Investor Presentaiton

ONENESS SNS812 (siRNA) Progress SNS812 targets the conserved region of SARS-COV-2. As of 2021.12.13, its target viral genome covers 99.8% of SARS-CoV2 strains including the Omicron variant according to NCBI database and GISAID ■ Contracted with CMO & CRO to proceed with GMP production and non-clinical toxicity studies. Plan to submit IND in 2022.H2 ■ SNS812 research data and results have been submitted to a renown international journal | 32

View entire presentation